Afatinib (BIBW2992)

Name: Afatinib (BIBW2992)
Brand: Selleck Chemicals
SKU: S1011
Rating: 5 (259 reviews)

For research use only.

Catalog No.S1011

259 publications

CAS No. 850140-72-6

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.

Selleck's Afatinib (BIBW2992) has been cited by 259 publications

Cancer Cell, 2021, S1535-6108(20)30609-7

PubMed: 33417832 ( click the link to review the publication )

Nature, 2020, 584(7822):608-613

PubMed: 32848220 ( click the link to review the publication )

Nature, 2019, 571(7763):127-131

PubMed: 31243371 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nat Med, 2017, 23(10):1167-1175

PubMed: 28920960 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):17

PubMed: 33461557 ( click the link to review the publication )

EBioMedicine, 2021, 64:103220

PubMed: 33529999 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(2)E752

PubMed: 33451095 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Cell Res, 2020, 10.1038/s41422-020-00409-1

PubMed: 32958903 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.3555.2020

PubMed: 33355298 ( click the link to review the publication )
Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01564-w

PubMed: 33288882 ( click the link to review the publication )

Oncogene, 2020, 39(20):3997-4013

PubMed: 32242147 ( click the link to review the publication )

Cancer Lett, 2020, 476:23-33

PubMed: 31958486 ( click the link to review the publication )

J Invest Dermatol, 2020, 3 pii: S0022-202X(20)31407-X

PubMed: 32376279 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):882

PubMed: 33082316 ( click the link to review the publication )

Cell Death Dis, 2020, 2;11(1):6

PubMed: 31919341 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 10(5):674-687

PubMed: 32213539 ( click the link to review the publication )

Oral Oncol, 2020, 112:105074

PubMed: 33142224 ( click the link to review the publication )

J Virol, 2020, JVI.02001-20

PubMed: 33361428 ( click the link to review the publication )

Antimicrob Agents Chemother, 2020, 1;AAC.00341-20

PubMed: 32482675 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):129

PubMed: 32066410 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(3):605-619

PubMed: 32036454 ( click the link to review the publication )

Am J Transl Res, 2020, 15;12(3):847-856 eCollection 2020

PubMed: 32269717 ( click the link to review the publication )

Cancer Res Treat, 2020, 10.4143/crt.2020.585

PubMed: 33070556 ( click the link to review the publication )

Toxicol In Vitro, 2020, 104928

PubMed: 32622998 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )
Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Korean J Parasitol, 2020, 58(3):249-255

PubMed: 32615738 ( click the link to review the publication )

Radiat Oncol, 2020, 15(1):58

PubMed: 32143669 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2020, 21(1):61

PubMed: 32795383 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Physiol Rep, 2020, 8(13):e14490

PubMed: 32652816 ( click the link to review the publication )

Genome Biol, 2020, 21(1):181

PubMed: 32727536 ( click the link to review the publication )

J Cancer, 2020, 11(1):241-250

PubMed: 31892990 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.30172

PubMed: 33230821 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:376

PubMed: 32774169 ( click the link to review the publication )

Neurooncol Adv, 2020, Dec;2(1):vdaa020

PubMed: 32226941 ( click the link to review the publication )

Sci Rep, 2020, 10(1):12982

PubMed: 32737414 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Oncogene, 2019, 38(30):5890-5904

PubMed: 31253872 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):266

PubMed: 31215502 ( click the link to review the publication )
Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Br J Cancer, 2019, 121(10):846-856

PubMed: 31607750 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Oncoimmunology, 2019,

PubMed: 30713780 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):733-742

PubMed: 30787176 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):920-928

PubMed: 30872380 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(6):1282-1292

PubMed: 31285959 ( click the link to review the publication )

Oncogenesis, 2019, 8(10):54

PubMed: 31570699 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(11):2233-2243

PubMed: 31467113 ( click the link to review the publication )

Gynecol Oncol, 2019, 153(1):158-164

PubMed: 30630630 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28881

PubMed: 31152452 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Front Physiol, 2019, 10:189

PubMed: 30971932 ( click the link to review the publication )
Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Transl Oncol, 2019, 12(6):852-858

PubMed: 31030101 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Clin Otolaryngol, 2019, 10.1111/coa.13434

PubMed: 31536667 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3317-3325

PubMed: 31432165 ( click the link to review the publication )

Pharmaceuticals (Basel), 2019, 12(4)

PubMed: 31703435 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Nat Struct Mol Biol, 2018, 25(6):454-462

PubMed: 29760531 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9):e8746

PubMed: 30021798 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(11):2594-2604

PubMed: 29298799 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Immunol Res, 2018, 6(12):1511-1523

PubMed: 30242021 ( click the link to review the publication )

Clin Cancer Res, 2018, 15;24(6):1436-1447

PubMed: 29127119 ( click the link to review the publication )

Theranostics, 2018, 8(12):3176-3188

PubMed: 29930721 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )
Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29880898 ( click the link to review the publication )

Cancer Discov, 2018, 8(9):1087-1095

PubMed: 29802158 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):830-854

PubMed: 29603584 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):441-462

PubMed: 29325228 ( click the link to review the publication )

Cancer Sci, 2018, 109(11):3657-3661

PubMed: 30255614 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Front Oncol, 2018, 8:432

PubMed: 30345256 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(42):16518-16527

PubMed: 30166343 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

Ann Thorac Surg, 2018, 105(2):363-370

PubMed: 29223420 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Biosci Rep, 2018, 38(6)

PubMed: 30420490 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Bladder Cancer, 2018, 4(1):77-90

PubMed: 29430509 ( click the link to review the publication )
J Am Chem Soc, 2018, 140(40):12785-12797

PubMed: 30256630 ( click the link to review the publication )

Sci Rep, 2018, 8(1):14896

PubMed: 30291293 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Theranostics, 2017, 7(4):974-986

PubMed: 28382169 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Oncogene, 2017, 36(47):6581-6591

PubMed: 28783173 ( click the link to review the publication )

Oncogene, 2017, 36(13):1873-1886

PubMed: 27694893 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2773

PubMed: 28492539 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 27913578 ( click the link to review the publication )

Neoplasia, 2017, 19(12):1012-1021

PubMed: 29136529 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Cancer Prev Res, 2017, 10(1):76-88

PubMed: 27756753 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 335:16-27

PubMed: 28942004 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(3):656-661

PubMed: 28756224 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )
Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29050315 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

BMB Rep, 2017, 50(3):150-155

PubMed: 28256196 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28881811 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28145866 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423495 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(1):133-41

PubMed: 26371512 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27207775 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27678331 ( click the link to review the publication )

Cancer Sci, 2016, 107(8):1134-40

PubMed: 27240419 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146311

PubMed: 26735495 ( click the link to review the publication )

Mol Med Rep, 2016, 13(3):2338-44

PubMed: 26782932 ( click the link to review the publication )
Oncotarget, 2016, 7(28):42859-42872

PubMed: 27374095 ( click the link to review the publication )

Cancer Immunol Res, 2016,

PubMed: 27799141 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )

Cancer Immunol Res, 2016,

PubMed: 27680026 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26623721 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(1):93-101

PubMed: 25384171 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4597-606

PubMed: 26138066 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

J Med Chem, 2015, 58(16):6589-606

PubMed: 26258521 ( click the link to review the publication )

Cancer Discov, 2015,

PubMed: 26243863 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: 25504185 ( click the link to review the publication )

Cell Tissue Res, 2015, 359(3):799-816

PubMed: ( click the link to review the publication )
Oncol Rep, 2015,

PubMed: 26503698 ( click the link to review the publication )

Arch Immunol Ther Exp, 2015, 10.1007/s00005-015-0330-5

PubMed: 25678473 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 25969993 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )

Anticancer Res, 2015, 35(4):2005-8

PubMed: 25862853 ( click the link to review the publication )

J Anal Methods Chem, 2015, 2015:215128

PubMed: 26101692 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25686822 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25537503 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5423-34

PubMed: 25189483 ( click the link to review the publication )

Cancer Res, 2014, 74(1):341-52

PubMed: 24177178 ( click the link to review the publication )

Oncogene, 2014, 33(25):3334-41

PubMed: 23873022 ( click the link to review the publication )

Anal Chem, 2014, 86(21):10568-75

PubMed: 25263480 ( click the link to review the publication )

Br J Cancer, 2014, 111(9):1750-6

PubMed: 25268372 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Histochem Cell Biol, 2014, 142(4):361-71

PubMed: 24824474 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0344-7

PubMed: 25341405 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )
Oncotarget, 2014, 5(24):12877-90

PubMed: 25375092 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Sci Transl Med, 2013, 5(199):199ra111

PubMed: 23966300 ( click the link to review the publication )

Eur J Cancer, 2013, 49(6):1458-66

PubMed: 23153706 ( click the link to review the publication )

Oncogene, 2013, 32(37):4427-35

PubMed: 23045273 ( click the link to review the publication )

Cancer Sci, 2013, 104(5):584-9

PubMed: 23387505 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(6):1663-71

PubMed: 22317763 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41017

PubMed: 22815900 ( click the link to review the publication )

Oncol Res, 2011, 19(10-11):471-8

PubMed: 22715590 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Targets

EGFR (L858R) ^[1] (Cell-free assay)	EGFR (wt) ^[1] (Cell-free assay)	ErbB4 ^[2] (Cell-free assay)	EGFR (L858R/T790M) ^[1] (Cell-free assay)	HER2 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1 nM	10 nM	14 nM

In vitro

BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HDLM-2	NFTvWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\lVWlEPTB;MD6wNFU4OiEQvF2=	M2TUV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KASUMI-1	NHfPSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwMEC5NVEh\|ryP	M3LK[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HCC2218	NX\tfotrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rxU2lEPTB;MD6wNFk5PyEQvF2=	NIfYblA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
KARPAS-45	MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NID2Zo1KSzVyPUCuNFE3PzFizszN	M4HpXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HSC-4	NIrUZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXf0SFlQUUN3ME2wMlAyPzR6IN88US=>	MmC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
CHL-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMEG4N\|kh\|ryP	M{HqOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KY821	M2PqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnuTWM2OD1yLkCyNFYh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-N87	Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTZW4lKSzVyPUCuNFI4PzNizszN	MnLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
DOK	NHXsOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnUcnptUUN3ME2wMlA{OTl2IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
DSH1	M3HUfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorDTWM2OD1yLkCzN\|E1KM7:TR?=	MnXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
MDA-MB-175-VII	MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHjUmxKSzVyPUCuNFM1OTZizszN	Mmi0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H2170	NXX0TVIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHwdYduUUN3ME2wMlA{PzJ6IN88US=>	MkjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
BT-474	M1\Me2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMES5PFYh\|ryP	M3[3NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EFO-27	NEjkb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;R[GlEPTB;MD6wOVE5OiEQvF2=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H720	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnSd25KSzVyPUCuNFU{OjVizszN	Mo\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
PC-14	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrMO4NqUUN3ME2wMlA2PjZ6IN88US=>	M1XoSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EC-GI-10	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\ZOWlEPTB;MD6wOVkyOiEQvF2=	MlLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
KYSE-450	NYjCUFJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwMEW5O\|gh\|ryP	MoO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
BPH-1	NGjCXmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml35TWM2OD1yLkC1PVg5KM7:TR?=	M{TlSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H292	NIe3fYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFi3d4xKSzVyPUCuNFYxQSEQvF2=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
H9	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMEexN\|Ih\|ryP	MnPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H526	M2GyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\3V4lKSzVyPUCuNFc5OjNizszN	NHz2Tlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H1623	NU\a[HUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWe1cIJZUUN3ME2wMlA5ODJ3IN88US=>	NHPCdZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
KYSE-140	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfQfVlKSzVyPUCuNFg{OyEQvF2=	M4Xr[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
Ca9-22	NUTrcG14T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDhN3FKSzVyPUCuNFg{PTNizszN	MoHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
AU565	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3OxO2lEPTB;MD6wPFUxPCEQvF2=	MmPiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
ZR-75-30	Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTabmZtUUN3ME2wMlA6PTR3IN88US=>	NF\zUIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H1770	M1G5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33WZmlEPTB;MD6xNFI5KM7:TR?=	MlraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
LB2241-RCC	MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDNTWM2OD1yLkGwPFg1KM7:TR?=	M3jlNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
CAL-39	NV3PWXN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEOweIxKSzVyPUCuNVE4QTJizszN	M4PMbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
UACC-893	NYPtNms1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjZToI{UUN3ME2wMlEyQDh3IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LU-65	MnPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWHlN4hQUUN3ME2wMlEzPjN\|IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HN	NVSyVWc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnT5TWM2OD1yLkGzNFc4KM7:TR?=	M1TTTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
TI-73	M1;EXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTBwMUS3NVUh\|ryP	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KU812	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\YTWM2OD1yLkG1OFU3KM7:TR?=	MkXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SW13	M4DqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nNWmlEPTB;MD6xOlIyPiEQvF2=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
BB30-HNC	Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInIZndKSzVyPUCuNVY2PzZizszN	NWe3VoViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HSC-2	MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwMU[4N\|ch\|ryP	NInFZ2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
BV-173	MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMUe1PVYh\|ryP	NWfSfoNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
CAL-27	M1POc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWThfVZMUUN3ME2wMlE4PjN4IN88US=>	NVLG[5BNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SBC-1	M1[3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfSdJNPUUN3ME2wMlE5QTV7IN88US=>	M{SxdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
CAL-33	M1XKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnDTWM2OD1yLkKwNVg1KM7:TR?=	MlfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H209	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTBwMkC0OkDPxE1?	MmX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
COR-L105	NEH5VVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\UdndnUUN3ME2wMlIyODh2IN88US=>	M1L4bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HSC-3	MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLRbpNKSzVyPUCuNlEyQThizszN	MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H69	NUnENGpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzmTWM2OD1yLkKxOFUyKM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MOLT-13	Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLDcnRIUUN3ME2wMlI{QTd3IN88US=>	M3K5W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
ML-2	M1\adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfZc4s2UUN3ME2wMlI1QDB{IN88US=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
IGROV-1	M1PUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMkW5OVIh\|ryP	NFyxb\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
TK10	M{DhTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUL2OGp3UUN3ME2wMlI3PzN6IN88US=>	NWLmflZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
EoL-1-cell	M4[4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwMk[4PVIh\|ryP	NWnI[pBqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HO-1-N-1	MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMke4OVMh\|ryP	M4rwOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
BHY	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwMki2OVUh\|ryP	NXu2[o9{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
LU-139	MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\YVGlEPTB;MD6zNFUyKM7:TR?=	NV\HTVFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
23132-87	NYS0WHh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEG5N3NKSzVyPUCuN\|E6OjNizszN	NWDMTGxDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
ACHN	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzr[5pjUUN3ME2wMlMyQTl2IN88US=>	MkjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
DoTc2-4510	M1jIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGW1[HlKSzVyPUCuN\|IzOTlizszN	NVW0TGFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
BB65-RCC	MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTBwM{S1PVMh\|ryP	Ml\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HLE	MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXoNFVKSzVyPUCuN\|UxPDZizszN	NIL2[Jc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HCC1419	NVj5VZZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DsWGlEPTB;MD6zOlQxQCEQvF2=	M2PENVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
A388	NXnPPXRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnsbYlKSzVyPUCuN\|Y5PTdizszN	Mn;nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NUGC-3	NY\BZnY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjIVHZEUUN3ME2wMlM5Ozd\|IN88US=>	NHjKNY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
KYSE-180	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHOTWM2OD1yLkO5NFg6KM7:TR?=	M3TKfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
TE-6	MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjvTWM2OD1yLkSwNlQ3KM7:TR?=	M4faeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
A498	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIe4XZlKSzVyPUCuOFA3PzRizszN	M1HYZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H1648	NIXw[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXKSpdKSzVyPUCuOFQyQDJizszN	M2jTZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
DU-145	NGXsT\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwNES4N\|Mh\|ryP	MkHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
CW-2	MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTpNHJ3UUN3ME2wMlQ3QTF2IN88US=>	NFu0[mQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
A431	NWn4b3B3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rmSWlEPTB;MD60PFI{OyEQvF2=	M4[1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SAS	M1izW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIOwXmtKSzVyPUCuOFg{QThizszN	MlvtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H2126	M3P5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrieZBKSzVyPUCuOVE6OjZizszN	M17W[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H358	Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\iTWM2OD1yLkWzNlEh\|ryP	NW\KV2xCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
FADU	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwNUS0NFQh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
ACN	NHr1dJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjTdWFKSzVyPUCuOVUxQTRizszN	MmLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HCC70	MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXOV5VKSzVyPUCuOVc3PjFizszN	Mn;lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H1838	NGntVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHJPXZKSzVyPUCuOlAzQTlizszN	NXjFeJpSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
CAL-54	MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDKNlNjUUN3ME2wMlYyPjJzIN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H1975	NF7l[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\XTWM2OD1yLk[xO\|I5KM7:TR?=	NUfCOWxJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
COR-L88	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nyTWlEPTB;MD62OFEyOyEQvF2=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
CTV-1	MnrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVq3SZNVUUN3ME2wMlY1Ozl{IN88US=>	NWHUN5p{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
EW-18	M1:1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXvcoNlUUN3ME2wMlY5Pjl6IN88US=>	Mkm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HCC1806	NE\a[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7s[ldKSzVyPUCuOlk3PjZizszN	NIXoVG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HuP-T4	NWCxXG9zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDlTWM2OD1yLk[5O\|Yh\|ryP	M4LsVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MDA-MB-361	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwN{K2OlIh\|ryP	MkjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H1573	NHv4VHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTBwN{O2N{DPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KU-19-19	MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\pPYxKSzVyPUCuO\|c1PjRizszN	NEO4bXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
COLO-678	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\IdJI4UUN3ME2wMlgxQDN2IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
C-33-A	MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;DcGlEPTB;MD64NVI6PyEQvF2=	NET3cHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
Calu-3	NUXNboE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTBwOEG0N\|Qh\|ryP	NYfoeY1xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
AGS	M3[wOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUX4fopqUUN3ME2wMlg{PjR6IN88US=>	MnvqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SCC-25	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnzZmVKSzVyPUCuPFQyPzFizszN	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
JVM-2	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDJVIVKSzVyPUCuPFgzQTlizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HCE-T	NWW1bFNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwOEi0Nlgh\|ryP	NULZ[3R4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
ES4	NV;qWJFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYfzd2RZUUN3ME2wMlk4QDN4IN88US=>	MmK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
EKVX	NGHMb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PrNWlEPTB;MT6wNVA3PCEQvF2=	Mo\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
D-542MG	M{LTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlT6TWM2OD1zLkCxNFY1KM7:TR?=	M1HUbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SW1116	NGKxUFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4G3eWlEPTB;MT6wNVI5PyEQvF2=	NYDvcVNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
5637	MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDwNo03UUN3ME2xMlAyPTFizszN	NGjaTok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HT-1376	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHmW\|FKSzVyPUGuNFE2OTNizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NB69	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M12xfmlEPTB;MT6wNlk1PSEQvF2=	M2j4bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
YKG-1	NFSwN3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XDZmlEPTB;MT6wOVQyQSEQvF2=	M{PGSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EW-3	NXroOXRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFO2V5VKSzVyPUGuNFc5QDNizszN	MknJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
GCIY	MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUW5dZZoUUN3ME2xMlA5OTB2IN88US=>	Ml\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SK-MES-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTFwMUG0PFch\|ryP	NH;3OIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
PANC-08-13	M4HNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTFwMU[0NVYh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	NE\xOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETQSoVKSzVyPUGuNVc2OTNizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SW954	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTFwMkCyNVQh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-SNU-5	NHGzdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTFwMkO5JO69VQ>?	NIXMfZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SW48	MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrNeVdFUUN3ME2xMlI2PDN{IN88US=>	NUjueG5pRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HT-3	M4PmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTFwMki3OVMh\|ryP	NXjGcFY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
ETK-1	MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXL4VmRWUUN3ME2xMlM4PDV4IN88US=>	NHHZSpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SCC-15	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTFwM{m0OVEh\|ryP	NFPER\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
DU-4475	Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\jWHlIUUN3ME2xMlQxOTJzIN88US=>	M4HSWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NB5	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmn1TWM2OD1zLkSxN\|E4KM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
CFPAC-1	NXXTWYJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTFwNEK0PVMh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H630	MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4jMV2lEPTB;MT60OVU5OiEQvF2=	MnzUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H82	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDuZoZKSzVyPUGuOVQxODZizszN	MlzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
ECC10	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTFwNUWzOlkh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
K5	M3TRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnz[2hKSzVyPUGuOVg{PTdizszN	M2Pmc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
ME-180	NXPXO\|c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPzTWM2OD1zLk[xNFk3KM7:TR?=	M3\rSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KYSE-410	NFnnT\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fNfmlEPTB;MT62OVY4OiEQvF2=	M1jqc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
G-401	NVnJ[4tCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTFwNke0NVMh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
TGBC24TKB	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoGxTWM2OD1zLk[4NlMh\|ryP	NXHFRXcyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
Detroit562	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDGR4JKSzVyPUGuO\|AyPTJizszN	M2C3[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
OE19	NUnUT3d7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDSW5dKSzVyPUGuO\|E2OTJizszN	NH31Z3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
CAKI-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTHTWM2OD1zLke4NlEyKM7:TR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
TE-12	NHnQO\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rOe2lEPTB;MT64NFQyPCEQvF2=	NYTz[49[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H1666	MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fQPWlEPTB;MT64NFk1QCEQvF2=	NHHoe4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
TE-1	NHjaVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rBcmlEPTB;MT64NVQ4PSEQvF2=	M3f5XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
CAL-12T	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLVTWM2OD1zLki4PVQ2KM7:TR?=	MkPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
TE-8	NX3QNI5jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPZPIlPUUN3ME2xMlkyOzd5IN88US=>	NWTjd5lQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
KYSE-270	MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTJwMEK3N\|Ih\|ryP	NX;CVo82RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
GMS-10	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTJwMEO1NVch\|ryP	Ml\yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
A2780	NGLzbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkP3TWM2OD1{LkC2Nlk1KM7:TR?=	NXnKcoN3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
OMC-1	MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlL2TWM2OD1{LkC4NVY6KM7:TR?=	M1zrT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
LoVo	M37XOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU[5N4Y4UUN3ME2yMlExPzl5IN88US=>	NX32PJVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
PANC-03-27	MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3RTWM2OD1{LkG2OlMyKM7:TR?=	NUjZUG1jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MDA-MB-157	NVm4TW4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3T0O2lEPTB;Mj6yNVgzQCEQvF2=	M4PQU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
CaR-1	NWniVIxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HzbWlEPTB;Mj6yPFI5OSEQvF2=	M1X1[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
769-P	NHzuc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUX2UokyUUN3ME2yMlI6ODN5IN88US=>	NHPvdpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NB7	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnyTWM2OD1{LkK5Olc3KM7:TR?=	M4WwS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MKN7	Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEniW3RKSzVyPUKuN\|U{OzVizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H1048	NX\KU485T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2K1e2lEPTB;Mj60PVE2QCEQvF2=	NXPWWZBVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
RCM-1	NWDmT\|Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLJTWM2OD1{LkWyPVM5KM7:TR?=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HT55	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjTb2ZKSzVyPUKuOVc{QCEQvF2=	M1;WVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HCC1569	NWTKcWo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DPWmlEPTB;Mj61PFI6PyEQvF2=	M3fiW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
LXF-289	NFXjb2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jOV2lEPTB;Mj62N\|U3PSEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
OVCAR-3	M{Lnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPRTWM2OD1{Lk[3NVY4KM7:TR?=	M4nPSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
TE-10	NXLh[\|NlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfvTWM2OD1{Lk[4NFc5KM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SNU-C2B	NYTocW92T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\lNGlEPTB;Mj62PFYyPiEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LB1047-RCC	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4m2OGlEPTB;Mj63OFg5QCEQvF2=	M1\Fc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SN12C	M3LQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTJwOUG5OlQh\|ryP	NF;1flQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
786-0	NEPZR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjiS21KSzVyPUOuNFY1ODhizszN	M1i4XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HT-29	M1PZRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{W5U2lEPTB;Mz6wO\|MxQSEQvF2=	MnXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
RPMI-7951	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTNwMEe1PUDPxE1?	NFLJSZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NBsusSR	NXHpNndyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXoTWM2OD1\|LkG4NlU1KM7:TR?=	MmDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NKM-1	NIDTZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGW1NZNKSzVyPUOuNVg4PDRizszN	MmrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
Capan-2	NH3PPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTNwNE[4O\|Uh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MKN1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrDTWM2OD1\|LkS3NVA5KM7:TR?=	MkXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
OAW-42	NH\JUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTNwNUCwNlYh\|ryP	NXfjdY55RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SKG-IIIa	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fxRWlEPTB;Mz61NlI{PyEQvF2=	NWHke5ZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
no-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmr5TWM2OD1\|LkWzOVY1KM7:TR?=	Moi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NY	NVHFdmJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vwSGlEPTB;Mz61N\|Y2PSEQvF2=	M{i0b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HEC-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPBTWM2OD1\|LkW4PVUh\|ryP	NIG5bVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H441	M4DVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;xT2lEPTB;Mz61PVg1OSEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H2009	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTCWmN2UUN3ME2zMlYyOjF4IN88US=>	M{HrT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
T47D	NUKwUmRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHJOnlsUUN3ME2zMlYzOjF5IN88US=>	NHvZVW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SNU-449	NGnxcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHJZZhKSzVyPUOuOlU5OjZizszN	NF3wXZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-SNU-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvKcmVKSzVyPUOuOlk4OzVizszN	NWfJWIFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
BT-20	NIqzd3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETnOXpKSzVyPUOuOlk4QTVizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LS-123	M4\0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTNwN{SyPFQh\|ryP	NIP4eoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
8305C	NWXGSW11T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTNwN{W5NVEh\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
OCUB-M	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTNwN{[xPFch\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KOSC-2	NH3QdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXwZYFKSzVyPUOuPFM1PTFizszN	NFrzN\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H1693	NXL0clRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnZNpVKSzVyPUOuPFQyQDFizszN	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
TE-9	NXfYdGxCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXzTWM2OD1\|Lki0N\|gzKM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MV-4-11	Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{m4Z2lEPTB;Mz64O\|k6PCEQvF2=	MmK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
GAMG	NUjOfGE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTNwOUGzNVQh\|ryP	M2j6OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KNS-62	Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fPR2lEPTB;Mz65OFc{OSEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MC116	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIj1UVZKSzVyPUOuPVU1QDlizszN	NVHyOYs4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
647-V	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfZZ3pIUUN3ME2zMlk5PDV{IN88US=>	NV;mNIZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
U-87-MG	MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTRwMUC0PFEh\|ryP	M4PwblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
RPMI-8226	M1LubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTRwMUG2N\|Eh\|ryP	NWnKNpIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SW1417	NFftPXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmn1TWM2OD12LkGyNVQ4KM7:TR?=	M1nFNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
LAMA-84	NF3heXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHOzeZlKSzVyPUSuNVcxOiEQvF2=	MmTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
LS-513	NIrlSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4CycGlEPTB;ND6zNVIyPyEQvF2=	MknDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
KLE	NIrLOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;vR5B[UUN3ME20MlQxQDF7IN88US=>	Mnf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HCT-116	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHqTWM2OD12LkSxNFA4KM7:TR?=	M1y4[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EPLC-272H	M2jNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTRwNEG1N\|Mh\|ryP	NXzQ[\|VwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
KS-1	NUXuNGdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LJdGlEPTB;ND61NFg5QSEQvF2=	NWjHNFU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HT-1197	M2HHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjTWFlKSzVyPUSuOVI3PjlizszN	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LCLC-97TM1	MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTRwNUO2PFYh\|ryP	MoC3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
ES5	NEjIZ\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXm[Y1KSzVyPUSuPFM4OjNizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
CTB-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDROWc{UUN3ME20Mlg1QDhizszN	NUDJOFZMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HL-60	M3jzb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXPJR\|UxRTRwOE[2NVEh\|ryP	NGixTJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
VM-CUB-1	NGGw[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXDWXlKSzVyPUSuPFY5OTlizszN	NF\jW5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MEG-01	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVS1OJA{UUN3ME20Mlk6PDB\|IN88US=>	M1jvR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KYSE-520	NH7wdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnudo1KSzVyPUWuNlA5OzlizszN	NFHhWpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HuO-3N1	M4XJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTVwMkSwOFMh\|ryP	M2r5W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SW620	NVjEbXE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTVwMkS5OlQh\|ryP	Ml7nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
U031	NEmxb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTVwMkW0NlQh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
TE-5	MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTVwNEC4OUDPxE1?	Mnf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H747	NWO2dpJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTVwNEK0O\|Ih\|ryP	NUn3PGVqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MG-63	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTVwNEi3OlIh\|ryP	NVPuT3JjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HC-1	NWXJcGhDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXyOVlKSzVyPUWuOVE5OzlizszN	M{PQXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HCC2998	NHnTdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXtTWM2OD13LkWyOlE2KM7:TR?=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TifWlEPTB;NT61OFU{PyEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KINGS-1	NF32cmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTzTWM2OD13Lk[wPVQ1KM7:TR?=	NH;iZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
D-423MG	MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjBNXB4UUN3ME21MlYyPzB3IN88US=>	M4fYRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SW962	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofhTWM2OD13Lk[yNFMzKM7:TR?=	NVXOeYlXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
LOXIMVI	NYW1Zo02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXZVHM1UUN3ME21MlY{QDd\|IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LS-411N	Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHhVllKSzVyPUWuO\|k1PDFizszN	Mn74QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H2291	M1jz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HyUWlEPTB;NT65PFk1OyEQvF2=	NH3PWow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
A549	M{TvdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPQfmVOUUN3ME22MlEzPTV\|IN88US=>	Mlv3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
LS-1034	NIntTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLyTWM2OD14LkKwO\|A3KM7:TR?=	NXjINGZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NB14	NFHpS\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTZwNEO4N\|Yh\|ryP	M3fEVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H1299	NFz2NIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPmTWM2OD14Lk[zNVcyKM7:TR?=	MoPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
BT-549	NVL4eohnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPPXYRrUUN3ME22MlY3QDh7IN88US=>	NYfj[lZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
J-RT3-T3-5	NIi5NodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3v5WWlEPTB;Nj64Olkh\|ryP	NGf0cZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SW756	NYLJfnN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUKyNIg{UUN3ME22MlkyOTd4IN88US=>	NYmzOJlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
DJM-1	Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLITWM2OD14LkmyNFEzKM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
GP5d	NI\NO5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTZwOUezPVQh\|ryP	NEHFN4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MOLT-4	NVvuNWpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\GTXRMUUN3ME23MlAzOTN3IN88US=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H28	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTdwMU[0NFUh\|ryP	NIrBN3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MN-60	M17vTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjsUppCUUN3ME23MlI5ODh7IN88US=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
RMG-I	NYqxO5VpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3sV5BKSzVyPUeuN\|kzQTZizszN	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
COLO-800	NEP1[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13oUGlEPTB;Nz60NVQ1PiEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
DB	NYPncplYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DCTGlEPTB;Nz62NVAxPSEQvF2=	NGfnfI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
Ca-Ski	MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXL3PXdlUUN3ME23MlY1OjV7IN88US=>	NEDUZXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HEL	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELC[YFKSzVyPUeuO\|EzODNizszN	MnX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NH-12	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Dm[GlEPTB;Nz63NlgxQCEQvF2=	NEPobmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
LB373-MEL-D	NIHiSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF2yOXRKSzVyPUeuO\|Y4PzFizszN	M3\sRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SW900	MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPBeIhEUUN3ME23MlgzOTJzIN88US=>	M{HmOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
JVM-3	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUWxVI8xUUN3ME23Mlg6PTl7IN88US=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
OAW-28	M4XZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTdwOUS1O\|gh\|ryP	MkLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
KURAMOCHI	M322Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGq2R5pKSzVyPUeuPVQ5OTFizszN	NFnTbWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
BE-13	NXH3c2dmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHPTWM2OD15Lkm4NVEzKM7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
VMRC-RCZ	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRThwMEG2PVch\|ryP	NFLDWW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H727	NYfBW444T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPxSplKSzVyPUiuNVA1OiEQvF2=	MoHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SW1710	M3Pq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRThwMUi1NVUh\|ryP	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
D-502MG	NWXEdHlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\YNmhKSzVyPUiuNlkzQDJizszN	M4fUSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H1993	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3YN\|M3UUN3ME24MlM{PjNzIN88US=>	Ml\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SCC-4	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PzOGlEPTB;OD60OFA2QSEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
HAL-01	NH7ifIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;wOJFPUUN3ME24MlUyQTFizszN	MnPXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
GT3TKB	NYDzXHNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYP2PHV4UUN3ME24MlY4QTZ2IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SK-OV-3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfCXHpKSzVyPUiuO\|E{OjlizszN	NHjzXos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
COLO-829	NV7SWHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnTTWM2OD16LkiwPVc3KM7:TR?=	NH7C[\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
OCI-AML2	NEPpZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXRTWM2OD16Lkm1OFgyKM7:TR?=	Mnr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
OS-RC-2	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDZ[nRKSzVyPUmuNFIyQSEQvF2=	M1:xeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
BFTC-909	M2rvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTCOJNKSzVyPUmuNFY4QTlizszN	NES3cZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
EW-11	MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTrTWM2OD17LkG3OlU{KM7:TR?=	M{PDVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HCE-4	NIHjbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDkSGo6UUN3ME25MlIyPTV6IN88US=>	M4TWT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
BALL-1	NHyxOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;3eGlEPTB;OT6yNVkxPyEQvF2=	NITQV5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SF539	M2G0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\UTWM2OD17LkKzOVYzKM7:TR?=	NGr6bIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
CAMA-1	M2PUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrJSmFKSzVyPUmuNlgyOjhizszN	M3zlTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
C32	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DQVGlEPTB;OT6zN\|A3PCEQvF2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H1703	MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjZbmt4UUN3ME25MlM1Ozd3IN88US=>	NXT2VWtbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H1650	NYLoN28{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPPfnFKSzVyPUmuOlA6PDZizszN	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H1563	NHKxWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfFb\|Q4UUN3ME25Mlc3ODNzIN88US=>	M{LrVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
CAL-85-1	M2fHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPDeZpKSzVyPUmuPFc{QDNizszN	NG[1Upo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
UM-UC-3	NIq4T5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\1TWM2OD17Lkm1NFMh\|ryP	NIS1XIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
BxPC-3	NInXcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPtXphsUUN3ME2xNE4xQTd{IN88US=>	NFL3S5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MHH-PREB-1	NHTBUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLOcmtKSzVyPUGwMlE6QTlizszN	NUPaVW04RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
DEL	MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPITWM2OD1zMD6zPVQ3KM7:TR?=	MoPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HuCCT1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPYeolIUUN3ME2xNE43ODN\|IN88US=>	M3LHdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
OVCAR-4	NHPqR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTFyLki4N\|Uh\|ryP	M4DRc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
CAL-72	NHzQ[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnT5TWM2OD1zMD65N\|kyKM7:TR?=	NFO1RYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HCC1954	MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYf1fGR7UUN3ME2xNU4xPzV2IN88US=>	Mn;6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
EFO-21	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3hN4RKSzVyPUGxMlExPDVizszN	MlPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
FTC-133	M2DkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;0XmlEPTB;MUGuNVQxPyEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SK-MEL-24	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTFzLkKzOlYh\|ryP	NXLqSYxDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
UACC-62	NVP5SW0yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnmyTWM2OD1zMT6yN\|Y5KM7:TR?=	Mlr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H650	NEi5d2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XUcWlEPTB;MUGuNlQyQCEQvF2=	NFvQbHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
ALL-PO	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPoVoFnUUN3ME2xNU4zPTF{IN88US=>	NULNUFFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
T84	NEez[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTFzLkO5NFch\|ryP	M{Tvc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
IST-MEL1	Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jMNGlEPTB;MUGuOFU2QSEQvF2=	M4LVZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SW626	MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\HNGlEPTB;MUGuOVc2PSEQvF2=	NV3lSotTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
RPMI-2650	MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTFzLkW4PFUh\|ryP	NHy0flM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MC-IXC	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2juUGlEPTB;MUGuOlczQCEQvF2=	NV;BW4tORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HOP-62	NHvUcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHuWo1KSzVyPUGxMlY4PjRizszN	Mk\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NOS-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTyTHM5UUN3ME2xNU44OTB7IN88US=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SW1573	NVHzSYd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrQdHZTUUN3ME2xNU44Ojl3IN88US=>	NXX2dmRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
WM-115	MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{T4eGlEPTB;MUGuO\|U5QCEQvF2=	NXm1TYtjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HuO9	M3T2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH30U3hKSzVyPUGxMlg4PzRizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
YAPC	M{LFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfPTWM2OD1zMT65NlU6KM7:TR?=	Mn3DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
MDA-MB-453	NGHMfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnQTWM2OD1zMT65OVE2KM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H596	MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zJNGlEPTB;MUKuNFM3QSEQvF2=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
A172	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTF{LkC3PVgh\|ryP	NIX4U5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
RS4-11	NELRPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DXRWlEPTB;MUKuNVczPSEQvF2=	Ml\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HCC1937	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTF{Lke1OlQh\|ryP	M1POelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SW837	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\qXmlEPTB;MUKuPVAzQCEQvF2=	NFnocFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NMC-G1	MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHiUlRKSzVyPUGyMlkzOzRizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
PFSK-1	MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTF\|LkC2JO69VQ>?	Mlu2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
DBTRG-05MG	MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofVTWM2OD1zMz6wOlMzKM7:TR?=	NG\Pc4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SK-UT-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jNZ2lEPTB;MUOuNVA5OyEQvF2=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
OVCAR-5	MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHYTWM2OD1zMz6xOVk{KM7:TR?=	NEDYfm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
8505C	M3XyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;wWmlEPTB;MUOuNlA3PyEQvF2=	NIXFcVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SK-MEL-1	NEXHem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjpW2VWUUN3ME2xN{44OTN3IN88US=>	NVzsemR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
LK-2	Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3PdWwyUUN3ME2xN{44PjN7IN88US=>	NUDGNodERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
OE33	NW\LOZdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\iTWM2OD1zMz63PFYh\|ryP	MkPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
Ramos-2G6-4C10	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{T4V2lEPTB;MUSuNFIxOiEQvF2=	M1u5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EW-13	NYnxepdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\FTWM2OD1zND6wN\|UzKM7:TR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H1793	NEftdYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPBS5ZKSzVyPUG0MlIxQDdizszN	Ml\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
BHT-101	M4DOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\rR\|dKSzVyPUG0MlI1OSEQvF2=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
RKO	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTF2LkWwO\|Uh\|ryP	NYHI[HpsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NEC8	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LTVGlEPTB;MUSuOVQ4OiEQvF2=	NX[1SJFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
PANC-10-05	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlH1TWM2OD1zND62NlQ4KM7:TR?=	NXXaZpZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H2030	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoryTWM2OD1zND62OFQ5KM7:TR?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
C2BBe1	NFzLNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY[4[3V3UUN3ME2xOE44PjRizszN	M2DkWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EM-2	NXLTZpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUO4ZmxnUUN3ME2xOE45PTd4IN88US=>	NIjsVHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HCC1395	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjyenBDUUN3ME2xOE46OzN6IN88US=>	NGHqRWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
A2058	NInjOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HjVGlEPTB;MUWuNFQxQSEQvF2=	NUTSN\|N1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SW1463	NHK5cG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGroZ\|lKSzVyPUG1MlA1QDVizszN	NH[4ZVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
J82	NVK2VIpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTF3LkC1O{DPxE1?	MnK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
CAL-120	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TPcWlEPTB;MUWuNVQ1PyEQvF2=	NEHVSZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
COLO-824	NGLlb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTF3LkG1O\|kh\|ryP	MmfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
LNCaP-Clone-FGC	Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTTZ4hmUUN3ME2xOU41OjR6IN88US=>	M{X5PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
CP66-MEL	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTF3LkS2PFgh\|ryP	NEm3WJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
OC-314	NF[5O4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjzXXN{UUN3ME2xOU41PzF2IN88US=>	Mk\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
OVCAR-8	NXexNIJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH[0S29KSzVyPUG1Mlg5PjFizszN	Mn;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
MFE-280	NUDvRm1[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTF4LkC0PFgh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MHH-NB-11	M2D5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTF4LkC4N\|kh\|ryP	NIXubHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SW1990	M4S1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnvboJKSzVyPUG2MlE4PTVizszN	MlLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
U-266	M3Xy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIq3XWxKSzVyPUG2MlIzQTlizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MFM-223	NX61W3ZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHORoJKSzVyPUG2MlM6PjVizszN	NYf5Rok5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
L-363	M4PkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnlTmlKSzVyPUG2MlQ2PzdizszN	M1XjcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MCF7	NUfkTXRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moj0TWM2OD1zNj60O\|I{KM7:TR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SK-MEL-3	M2TaNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HQWWlEPTB;MU[uOFc5PyEQvF2=	M3fVSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HH	NHq3R3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUD6R4dmUUN3ME2xOk42OTZ{IN88US=>	MnjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
no-10	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkT2TWM2OD1zNj62N\|Q{KM7:TR?=	NG\M[II9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HuP-T3	MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTF4Lk[1O\|Yh\|ryP	M1HYPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
QIMR-WIL	MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTF4LkexNFUh\|ryP	M3TnO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H1092	M2jLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTF4LkizNVYh\|ryP	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MZ2-MEL	NX7mUYZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlS3TWM2OD1zNj64OFA{KM7:TR?=	NIP5cZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
ES3	MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTF4LkmxN\|Qh\|ryP	NG\wfZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
COLO-684	NYTDfohRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYW1boU1UUN3ME2xOk46PDd5IN88US=>	NWrLSItFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H661	NFrZfIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvsbYxZUUN3ME2xOk46Pjl2IN88US=>	M4DobVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
CP50-MEL-B	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrHZYhKSzVyPUG3MlA{PDNizszN	Mlu2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H2405	NIW0RpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXaZ3JFUUN3ME2xO{4yQTd2IN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
U-2-OS	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHyeHlKSzVyPUG3MlU{ODdizszN	M3z2S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
RERF-LC-MS	MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFX3eZVKSzVyPUG3MlU2ODhizszN	MojzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H2342	NEfnOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYXNfHJUUUN3ME2xO{42PTdizszN	MlfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
ES8	Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzuN\|dpUUN3ME2xO{43ODh5IN88US=>	NFrMTIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MOLT-16	M2\mNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULqd3lzUUN3ME2xO{45QTN2IN88US=>	MmjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
RH-18	NGX4NHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTF6LkCwN\|Uh\|ryP	NFf0ZZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
D-283MED	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jpSmlEPTB;MUiuNFA5QCEQvF2=	NXjle2VHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
RCC10RGB	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofVTWM2OD1zOD6wOVU6KM7:TR?=	NFSyfmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H1437	NWDTV4NPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTF6LkG2OFEh\|ryP	NF\BUGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SW982	NVTjfZRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInUNXlKSzVyPUG4MlI3PzFizszN	M{PSPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
IST-MES1	NWDnenVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfZTWM2OD1zOD60OFI5KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
A704	MlrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTF6LkS3OVMh\|ryP	NFm2Tow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
ESS-1	NEDOc4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPaRXR1UUN3ME2xPE42OjB3IN88US=>	M4Tsb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SCH	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjRXHBKSzVyPUG4MlY1PTZizszN	MlXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
COLO-320-HSR	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETTR4lKSzVyPUG4Mlc1PiEQvF2=	M1vNN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
Mo-T	Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrFOYhoUUN3ME2xPE45OjB2IN88US=>	NFj6So49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
Saos-2	M2D5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfhTWM2OD1zOT6xNVYzKM7:TR?=	NWS2b49qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SW684	NVjKS3dqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DsemlEPTB;MUmuNVMzPiEQvF2=	M{T3flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KMOE-2	NUSzd41JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\sXoY5UUN3ME2xPU4zOjR{IN88US=>	M4j0dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MMAC-SF	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nPbWlEPTB;MUmuNlYxPyEQvF2=	NXqzPG9{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
JAR	Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\sNVJQUUN3ME2xPU4zQTlizszN	NGrFcW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
SK-MEL-28	NIjDdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUP1TINKUUN3ME2xPU4{OzZ\|IN88US=>	NUPhPVlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
KNS-81-FD	NF\JPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrFTWM2OD1zOT61OFY5KM7:TR?=	MlHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
ES7	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1y0emlEPTB;MUmuOlI6OiEQvF2=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
AsPC-1	M{P1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;UcY5KSzVyPUG5MlY1PzFizszN	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H1155	NUny[nlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTvTWM2OD1zOT63NlM5KM7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KYSE-510	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTF7Lki3OFgh\|ryP	NXTl[4xQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
ES1	NHf5[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnkOHFKSzVyPUG5MlkzOTNizszN	NG\TUmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
PC-3	Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILl[ohKSzVyPUG5Mlk3ODRizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
GCT	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3aPGxKSzVyPUKwMlMxOjZizszN	MoK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
KARPAS-299	NXKzTGE6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3ywfWlEPTB;MkCuN\|QzOiEQvF2=	NHL0Xlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
DOHH-2	M{frR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTJyLkW0OlMh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
COLO-741	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLWTWM2OD1{MD62OkDPxE1?	NFfy[Ho9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H1395	M1TvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2exOmlEPTB;MkCuOlY6PyEQvF2=	MkGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HCC1187	M1HxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTJyLk[3N\|Qh\|ryP	M4fiblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
Becker	MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkezTWM2OD1{MD63NlAyKM7:TR?=	Mn3aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
LU-134-A	NHvReFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUH4c2xpUUN3ME2yNU4yODJ4IN88US=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MKN45	NWH3enRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTJzLkG1OVEh\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LC-2-ad	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfaW3hmUUN3ME2yNU4zPzJ7IN88US=>	M3v0[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EW-24	NUj5blN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknnTWM2OD1{MT6zPVQ2KM7:TR?=	MlTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SK-N-AS	Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXmTWM2OD1{MT64Nlc3KM7:TR?=	NFPTcoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H2052	M{TSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTJzLki5OlMh\|ryP	Mn3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
A4-Fuk	NWXJ[XpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTJ{LkG0NVkh\|ryP	MmXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NB10	NWDmO4hvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HofWlEPTB;MkKuNlM4OSEQvF2=	MlLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
CHP-212	MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHQTJU5UUN3ME2yNk4{OjJ{IN88US=>	MmntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
KM12	M3vqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{j3U2lEPTB;MkKuN\|U3KM7:TR?=	MkPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
JEG-3	M1\SUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTJ{LkO3PEDPxE1?	M1PoXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
LN-405	MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVm0RlB4UUN3ME2yNk42QTF\|IN88US=>	Mnv0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HCT-15	NHPWdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4e0fWlEPTB;MkKuO\|Q1OSEQvF2=	NF:4R5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MLMA	NVz2SZVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVe4TnBnUUN3ME2yNk44PDdizszN	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
GI-1	M2TM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTJ{Lke2OVgh\|ryP	NYXtbZh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
RT-112	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnWWYNKSzVyPUKyMlg3OTZizszN	NWTSV3lvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MPP-89	NEftTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWW3UFFJUUN3ME2yNk45PjZzIN88US=>	M{\IcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
A3-KAW	NIHkNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHuT5RKSzVyPUKzMlExODNizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KALS-1	NXjaU3Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jwfWlEPTB;MkOuNVQyPCEQvF2=	M{DMUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
SF126	NHPxSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2r2WmlEPTB;MkOuOlkzPCEQvF2=	NWTheWF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SiHa	NXXYUFNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHrTWM2OD1{Mz65N\|I4KM7:TR?=	NVixU3N5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MDA-MB-415	Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1z5fWlEPTB;MkOuPVQ6QSEQvF2=	MnrKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
Daoy	NGXJcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF74ZolKSzVyPUK0MlEzPiEQvF2=	Mn32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
COR-L23	NYrjUFZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnONZpnUUN3ME2yOE4yPzZ5IN88US=>	NFjxTGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
KG-1	Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTJ2LkG5Nlgh\|ryP	M{fKdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
L-428	M{DFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEO4WIRKSzVyPUK0MlU4QTFizszN	M1;oWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H520	MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIe0OIFKSzVyPUK0Mlg5PjFizszN	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
COLO-792	NYHEeFVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUm0VHVWUUN3ME2yOU4zPzN{IN88US=>	NWCxfGQzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NB12	M17LbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHUN45KSzVyPUK1MlI6PDdizszN	NXWxfG1ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
GAK	Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlu4TWM2OD1{NT6yPVY{KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SW780	NIe1eHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\iXGxKSzVyPUK1MlMzPjRizszN	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
GB-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWP2RmI4UUN3ME2yOU41ODZ7IN88US=>	MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
P12-ICHIKAWA	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrVTWM2OD1{NT60O\|g2KM7:TR?=	NYXBSGk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H1651	M{L0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fyXGlEPTB;MkWuOVk4KM7:TR?=	NU\keVBnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
KE-37	MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXaZWZKSzVyPUK1Mlc{OTVizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
CCRF-CEM	M3nwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jTVWlEPTB;MkWuPVY4KM7:TR?=	Mli2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SF295	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzvNIZKSzVyPUK2MlA1OjVizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
G-361	NXHxe4FKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vJPWlEPTB;Mk[uNVAzPyEQvF2=	NFez[VU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HOP-92	NYr5WYhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInGSmtKSzVyPUK2MlEzOjZizszN	M2DobVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
UMC-11	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrv[VlKSzVyPUK2MlQ2OTRizszN	NGTDXpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
IST-SL1	MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInCWYdKSzVyPUK2MlY2QTFizszN	NHr4RW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
TE-11	NILFd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfOTWM2OD1{Nj63O\|UzKM7:TR?=	Mn7DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H1304	NH3hV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTJ4LkmxNFgh\|ryP	NYrCeItPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SJSA-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPJVFJqUUN3ME2yO{4xOTd4IN88US=>	NWDzTYZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
BCPAP	NYHrVYNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;yZWlEPTB;MkeuNVM4KM7:TR?=	NV3wS4pYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
HTC-C3	NUPySmliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTJ5LkK1OlEh\|ryP	M3zYNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EW-16	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTJ5LkK5OFch\|ryP	MkPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HT-144	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PMTWlEPTB;MkeuOFA{OiEQvF2=	MkX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
MHH-ES-1	NITvd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTJ5LkS0OFch\|ryP	NGnoTXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
T98G	MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPFTWM2OD1{Nz61PFQ3KM7:TR?=	NWXJ[WJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
RPMI-8866	NEX1[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFyzbIZKSzVyPUK3Mlc2PjJizszN	MkD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
BEN	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTQcm9KSzVyPUK3Mlg2OTdizszN	M2XtT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MDA-MB-231	MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfkTWM2OD1{OD6yO\|k2KM7:TR?=	NFf3b3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
HuH-7	NXn2RlZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjhboVKSzVyPUK4MlQxOjhizszN	MnziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SK-N-FI	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2f1WmlEPTB;MkiuOFM{KM7:TR?=	NF;MU5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
AN3-CA	M4L2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\ZV2lEPTB;MkiuOFM6PSEQvF2=	M2\We\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EGI-1	MnfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TsWmlEPTB;MkiuOVkzQCEQvF2=	NXzhSnhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
697	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPWNXJoUUN3ME2yPE43OzNzIN88US=>	MmrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
TCCSUP	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PFe2lEPTB;MkiuOlQyQCEQvF2=	Ml3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
GR-ST	M1jnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvEfmlKSzVyPUK4MlY3QTZizszN	MofHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SK-N-DZ	NYTQPFhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPLeI1KSzVyPUK4MlY5QDVizszN	NVLoVXBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MIA-PaCa-2	M4HJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTJ6Lke5OVkh\|ryP	MmS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
IGR-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLLO5lKSzVyPUK4Mlg5PzRizszN	MlTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
BFTC-905	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLKeGpiUUN3ME2yPU4zPzB3IN88US=>	M1K0dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H1581	M3HoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYj2clZzUUN3ME2yPU4{OTR3IN88US=>	NIO3UFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
RD	NETrSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTJ7LkWyN\|Mh\|ryP	NXjq[ZJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SF268	NVroZ3JLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDW[YNKSzVyPUK5MlU6OzFizszN	MmnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SHP-77	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHuTWM2OD1{OT62NVgzKM7:TR?=	MofMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
D-566MG	M2DvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGCxWWNKSzVyPUK5Mlk{QTNizszN	MlHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
TGBC1TKB	NEfvSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml[4TWM2OD1\|MD6xNlM5KM7:TR?=	M2XTe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MEL-HO	M2XIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1X0bWlEPTB;M{CuNVQzOyEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SJRH30	MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTNyLkKxNFgh\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
D-336MG	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTETWM2OD1\|MD6yPFkzKM7:TR?=	Mn7UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
C3A	NEnLfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PMeGlEPTB;M{CuNlkzPyEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
Calu-6	NX\oOWprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HDU2lEPTB;M{CuNlk3OyEQvF2=	NWXYZ291RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MZ1-PC	NGC5SlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnJcHJ[UUN3ME2zNE4{QTNizszN	M{\CfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KYSE-70	NXfQOnkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;vUJc2UUN3ME2zNE42OTF2IN88US=>	NEjRSnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
CAPAN-1	NGT2cXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrxUXdKSzVyPUOwMlUyQDFizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
DK-MG	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4qxdWlEPTB;M{CuOVQ2PiEQvF2=	MlPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SK-HEP-1	MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTNyLk[zNlYh\|ryP	NFW3Rno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
MS-1	NHXvR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTNyLki4PFkh\|ryP	NIXDXnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
GI-ME-N	M1\YVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{Tm[2lEPTB;M{GuNFU4OSEQvF2=	M1;1WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H510A	Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnmxTWM2OD1\|MT60NFA3KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NB17	NEDlUnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1u4dWlEPTB;M{GuOVE5PSEQvF2=	NWHWcFVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
639-V	NXTYOm17T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7GTWM2OD1\|MT61NlQ{KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
CAL-51	M3W3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkH4TWM2OD1\|MT61OlY4KM7:TR?=	MlywQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HGC-27	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLaTWM2OD1\|MT61PFc{KM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
GOTO	NHz2RldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFy5N2pKSzVyPUOxMlg2ODZizszN	Ml3zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
ChaGo-K-1	Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTN{LkCwO{DPxE1?	NWPCbFZYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
RO82-W-1	MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDFTWM2OD1\|Mj6xOlA1KM7:TR?=	NXn4W5M2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SH-4	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPV[FBKSzVyPUOyMlE5PThizszN	M1n5bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
A204	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fMU2lEPTB;M{KuOVA3QSEQvF2=	M4fQZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
DMS-273	NF\RUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1T1SWlEPTB;M{KuOVMzOiEQvF2=	M1m5TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KGN	MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\0R2NKSzVyPUOyMlY{OyEQvF2=	Mn3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SK-MEL-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGP4S5dKSzVyPUOyMlY2OjdizszN	M3e1bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H2228	Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIG4cFdKSzVyPUOyMlY3ODJizszN	M4HoNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
MKN28	M4PQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUO2WGNzUUN3ME2zNk44QDN6IN88US=>	NGP2cVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
H-EMC-SS	NFXubo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XDTWlEPTB;M{KuPVY4QCEQvF2=	NEDqcFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
ATN-1	NFHQXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTN\|LkG0NVYh\|ryP	NXHtUGNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
D-263MG	NFjTW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDwTWM2OD1\|Mz64N\|c5KM7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LU-135	NGnwdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTrU2c6UUN3ME2zN{45QDJ7IN88US=>	Mo[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
C8166	NIrrOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE[ybVRKSzVyPUOzMlg5PTRizszN	NHL0VpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
T-24	NVXJdFFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXDTWM2OD1\|ND6wNlA2KM7:TR?=	NUnzdGlqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
Mewo	M4XW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILXOo1KSzVyPUO0MlE{PDlizszN	M2S3VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
22RV1	NF33O2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfPUFBZUUN3ME2zOE4yPzV2IN88US=>	NGribZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
KM-H2	NXm2bJRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHTRXNPUUN3ME2zOE4yPzd7IN88US=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H2122	M1HtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XmcGlEPTB;M{SuN\|Q4OSEQvF2=	M{H6V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
ABC-1	NH[4XnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\ONJplUUN3ME2zOE4{Pjl\|IN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NCI-H1355	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWi3[Gx[UUN3ME2zOE4{QDh7IN88US=>	NGn3OpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NOMO-1	M3HtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\NTWM2OD1\|ND61O\|A{KM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MZ7-mel	M1nFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TtT2lEPTB;M{SuOlQ5PyEQvF2=	MlnMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H810	M3HRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHIdFdxUUN3ME2zOE44Ojd6IN88US=>	NVrocZo3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
D-392MG	NHTZT\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvKTJZQUUN3ME2zOU4xPTZ3IN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LB771-HNC	M1uzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXSTWM2OD1\|NT6xOlU5KM7:TR?=	NEDqcJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
COLO-679	M4XpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTN3LkO4PEDPxE1?	NU[2[5RtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SK-PN-DW	NI\ufFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1v1PGlEPTB;M{WuOFM3QSEQvF2=	NInPWWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
VA-ES-BJ	MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXK5WIw3UUN3ME2zOU41PjR7IN88US=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KNS-42	Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3uTWM2OD1\|NT61PFI3KM7:TR?=	Mn;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
RVH-421	NYTMcm5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjVNXZEUUN3ME2zOU44PjR3IN88US=>	NFG4eow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
P30-OHK	NWjuNYdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jMRmlEPTB;M{WuPFc2OiEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
G-402	MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVmxeHBoUUN3ME2zOU46QDZ5IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
S-117	M3XWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTN4LkOwNFgh\|ryP	NXXaOXR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
RXF393	M4nLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jRXmlEPTB;M{[uN\|c5PSEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LCLC-103H	NIjhZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIS3TJZKSzVyPUO2Mlc5ODNizszN	NGrIcYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
U-118-MG	NXzGRWg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEW4S\|BKSzVyPUO2Mlg5PDdizszN	MmLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
8-MG-BA	NIrXWnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG[3Z5VKSzVyPUO2Mlk1QDNizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
MFH-ino	NVjhOolXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTN5LkOzO\|Eh\|ryP	MlzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
NCI-H23	M{W0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXzTWM2OD1\|Nz60NVk3KM7:TR?=	M{O1fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
NCI-H446	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[2VohKSzVyPUO3MlQ5PjJizszN	NYnNSGRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
LU-99A	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7s[ZVjUUN3ME2zO{42PzNzIN88US=>	M17L[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KP-N-YN	M{my[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDlTWM2OD1\|Nz62NVk2KM7:TR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SCC-9	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTN5Lke4N\|gh\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
EFM-19	NUPMdZhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDm[\|lKSzVyPUO3Mlc6PjdizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
A427	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGK0SIRKSzVyPUO3MlkyODdizszN	NIrCVWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
LB831-BLC	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVT0NWVqUUN3ME2zPE43ODN7IN88US=>	MnG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HOS	NXOydY5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTN7Lk[yO\|Mh\|ryP	MoCzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
LAN-6	NXTDUYJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInMVYpKSzVyPUSwMlAyOTJizszN	Mnv2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
U251	NUXZOlF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELKN\|BKSzVyPUSwMlQxPTRizszN	MmHkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SNU-387	NWi1UmxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTNTWM2OD12MD60OVU{KM7:TR?=	M3uzb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
DMS-79	M{TKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH62eJZKSzVyPUSwMlU5QDlizszN	NYLBVId2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
SK-LU-1	M2Toemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknETWM2OD12MD62OVY5KM7:TR?=	M{\HPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HT	MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTRyLk[2N\|kh\|ryP	M{nF[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
KP-N-YS	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETKTFBKSzVyPUSwMlY4PjhizszN	MmrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
DMS-114	MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTGRpB1UUN3ME20NE45Ozd2IN88US=>	M{j1R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HUTU-80	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWK2NVBPUUN3ME20NU4xPTZ7IN88US=>	NFrhcVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
ONS-76	NWTNeoVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvQTWM2OD12MT60O\|A6KM7:TR?=	NWewcol[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
A673	NFvtXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTRzLkWxOVch\|ryP	M{Dvb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
HPAF-II	M1jtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\sUXVKSzVyPUSxMlY4ODlizszN	MkewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
UACC-257	MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfJTWM2OD12MT63N\|Y6KM7:TR?=	NX\QemF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
EW-22	M1n3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fwcGlEPTB;NEGuPFY6PyEQvF2=	NXnhRZN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H1755	M2LZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTRzLki3NlUh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
KYSE-150	MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPFS5ZtUUN3ME20Nk4yPzh{IN88US=>	NFvwSFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
CGTH-W-1	NUfFUXVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17Bd2lEPTB;NEKuOFk2PSEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
NB13	NWDzWFlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXuyd\|UxUUN3ME20Nk43OjF5IN88US=>	MnqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
SW872	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDoTWM2OD12Mj62N\|MyKM7:TR?=	NEezWHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
KP-4	NFzkW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkO4TWM2OD12Mj64PFMzKM7:TR?=	Mmn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HCC38	NVTWPGJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrQUI9KSzVyPUSyMlk3OThizszN	NFXLNFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
BB49-HNC	NWSwcIYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTR\|LkKzOVYh\|ryP	NVPKRpJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
CAL-62	M13ITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3O2fWlEPTB;NEOuOFAzQCEQvF2=	NImzfYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H2029	NHKwZ3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTR\|LkW1PFEh\|ryP	NXnOZ2Z2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
M14	NULxUGpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HXWmlEPTB;NESuNVM{OiEQvF2=	NF;3U5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
COLO-680N	Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjYU3JKSzVyPUS0MlM{QSEQvF2=	MnLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
Hs-578-T	NG\ad2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPYTY5SUUN3ME20OU4xOjl2IN88US=>	NYjNfZhORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
MSTO-211H	M3fqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHCNHpKSzVyPUS1Mlk1QDJizszN	M2n3Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
EW-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIKxOXBKSzVyPUS1Mlk3QDlizszN	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
SW948	M3nWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfqemEyUUN3ME20Ok41PDZ{IN88US=>	NYfuVZF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTF5M{[1OU8oRlODTlfFVlww[T5?
NCI-H460	M3K2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvGTWM2OD12Nj61NlMh\|ryP	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
CAS-1	NFrocWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlqyTWM2OD12Nj63O\|AyKM7:TR?=	NHTEdFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
TGBC11TKB	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrVZ5pXUUN3ME20O{4yPzd5IN88US=>	MmTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
HD-MY-Z	NX\BOFJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTR6Lke4OkDPxE1?	NGfJW4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H226	M4X0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml34TWM2OD12OT63O\|g2KM7:TR?=	Moi0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVE4OzZ3NT:nQnNCVkeHUkyvZV4>
PA-1	MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4GzU2lEPTB;NEmuPFM{PSEQvF2=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>
LB2518-MEL	NFnMdXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXRUY5HUUN3ME20PU45PzJ\|IN88US=>	M{TWRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEyPzN4NUWvK\|5USU6JRWK8M4E,
A101D	NHL3cYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTOfFhWUUN3ME20PU46PDJ3IN88US=>	NEfTW2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOTd\|NkW1M{c,W0GQR1XSQE9iRg>?
NCI-H2087	NGjT[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTR7Lkm2PFIh\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNVc{PjV3Lze+V2FPT0WUPD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CIP2A / p-AKT / AKT / PARP; PubMed: 25537503 Oncotarget Time-dependent effects of afatinib on CIP2A, p-AKT and apoptosis-related proteins in the sensitive H358 and resistant H460 cells. Cells were exposed to 10 μM afatinib for up to 48 hours. Immunoblots were scanned and quantitated to determine the ratio of the level of CIP2A to actin. Data are mean ± SD. n = 3 for the different time intervals. p-EGFR / p-IGF1R / p-ERK / p-AKT; PubMed: 26052929 Mol Carcinog Effects of afatinib on EGFR and IGF1R Signaling Pathways. H1975 cells were treated with afatinib with various doses and cell lysates were subjected to Western blot analysis. Afatinib effectively inhibits p-EGFR and p-ERK while p-AKT was partially inhibited. IGF1R phosphorylation was increased upon afatinib treatment in H1975 cells. p-VEGFR2 / VEGFR2 / JAG1 / DLL4 / NICD1 ; PubMed: 28533486 Oncotarget HUVECs were cultured in the presence of Vatalanib (100 nM) or DBZ (10 nM) for 1 h and then treated for 15 min with rhgal-3 (37 nM) and cultured for additional 6 hrs. After this period, the total protein was isolated and the protein levels of galectin-3, NICD1, DLL4, JAG1, VEGFR2 and VEGFR2-p were assessed by Western blot. β-actin was used as a loading control.	25537503 26052929 28533486
Growth inhibition assay	Cell apoptosis; PubMed: 25537503 Oncotarget Dose-dependent effects of afatinib on apoptosis. Data are mean ± SD. n = 3 for each concentration. , p < 0.05, *, p < 0.01, vs. no afatinib. Cell viability; PubMed: 26515464 Oncotarget A. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars indicate standard deviation.	25537503 26515464
Immunofluorescence	p65; PubMed: 26317651 Oncotarget Effects of different treatments on the nuclear translocation of the NF-κB subunit p65. A2780T cells were treated with 2.5 μM afatinib for 48 hours, or 10 μM PDTC for 2 hours. Subsequently, the NF-κB subunit p65 (red) was localized by immunofluorescence and a confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar = 10 μM. vacuoles; PubMed: 29713246 Cancer Cell Int Autophagy activation upon treatment with Afatinib and Sorafenib was validated using immunofluorescence in order to visualize a creation of autophagosomes; ×60 magnification. DMSO treatment was used as control. Green—autophagy vacuoles; Blue—Hoechst, nuclear staining.	26317651 29713246

In vivo

Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase activity assays: The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
Cell Research: ^[1]	- Collapse Cell lines: NSCLC cells Concentrations: 0-10 μM Incubation Time: 1 hour Method: 1 × 10⁴ NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 10⁴ cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Athymic NMRI-nu/nu female mice Dosages: 20 mg/kg Administration: Oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (199.61 mM)
	Ethanol	15 mg/mL (30.86 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afatinib (BIBW2992) SDF

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	850140-72-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04497584	Not yet recruiting	Drug: Afatinib + Prednisone	Advanced Squamous Non Small Cell Lung Cancer	University of Texas Southwestern Medical Center	March 1 2021	Phase 2
NCT04413201	Recruiting	Drug: Afatinib\|Drug: Osimertinib	Non-squamous NSCLC	Michael Hopp\|Boehringer Ingelheim\|Johannes Gutenberg University Mainz	September 11 2020	Phase 4
NCT04206787	Recruiting	Drug: Afatinib	Non-squamous Non-Small Cell Lung Cancer	Boehringer Ingelheim	May 20 2020	--
NCT04158947	Recruiting	Drug: Afatinib\|Drug: T-DM1	HER2-positive Breast Cancer\|Brain Metastases	xuexin he\|Second Affiliated Hospital School of Medicine Zhejiang University	May 10 2020	Phase 2
NCT03711422	Unknown status	Drug: Afatinib	Non-small Cell Lung Cancer\|Leptomeningeal Disease\|Central Nervous System Metastases	National Cancer Centre Singapore	October 2018	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.
Classic EGFR Inhibitor

WZ4002 : Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Related EGFR Products

Erlotinib ^New

Erlotinib (CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib (GSK572016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)